Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study

Figures & data

Table 1. Clinical features and demographic characteristics of the patients.

Number of patients	30
	Mean (SD)
Age at atopic dermatitis onset	2,92 (2,47)
Age at start of dupilumab	15,93 (1,84)
Mean EASI at baseline	23,25 (4,15)
Mean P-NRS at baseline	8,3 (1,44)
Mean S-NRS at baseline	6,47 (2,85)
	N (%)
Female	20 (66,7)
Atopic comorbidities:
Allergic Asthma Rhinitis Conjunctivitis	10 (33,3)
	10 (33,3)
	2 (6,7)
Previous treatment with cyclosporine	8 (26,7)
Dosage of dupilumab
200 mg 300 mg	8 (26,7)
	22 (73,3)

SD: standard deviation; mEASI: mean eczema area and severity index; S-NRS: sleep numerical rating scale; P-NRS: pruritus numerical rating scale.

Figure 1. mEASI (top left), EASI75 and EASI90 (top right), S.NRS (bottom left) and P-NRS (bottom right) throughout the study period. mEASI: mean eczema area and severity index; S-NRS: sleep numerical rating scale; P-NRS: pruritus numerical rating scale

Data availability statement

Data available on request from the authors.